Table 2 Clinicopathological characteristic of patients with CRC stratified by PIV and AGR cutoffs in the training cohort.
Characteristics | Overall patients N = 470 | High PIV (≥ 426.8) N = 82 | Low PIV (< 426.8) N = 388 | P value | High AGR (≥ 1.4) N = 306 | Low AGR (< 1.4) N = 164 | P value |
|---|---|---|---|---|---|---|---|
Age, median (IQR) | 62 (52, 69) | 59 (50, 70) | 62 (52, 69) | 0.475 | 59 (50, 67) | 65 (59, 73) | < 0.001 |
Gender | 0.867 | 0.015 | |||||
Male | 279 (59.4%) | 48 (58.5%) | 231 (59.5%) | 194 (63.4%) | 85 (51.8%) | ||
Female | 191 (40.6%) | 34 (41.5%) | 157 (40.5%) | 112 (36.6%) | 79 (48.2%) | ||
BMI | 0.332 | 0.037 | |||||
< 18.5 | 14 (3.0%) | 4 (4.9%) | 10 (2.6%) | 5 (1.6%) | 9 (5.5%) | ||
18.5–24 | 203 (43.2%) | 38 (46.3%) | 165 (42.5%) | 136 (44.4%) | 67 (40.9%) | ||
24–28 | 189 (40.2%) | 27 (32.9%) | 162 (41.8%) | 129 (42.2%) | 60 (36.6%) | ||
≥ 28 | 64(13.6%) | 27 (32.9%) | 51 (13.1%) | 36 (11.8%) | 28 (17.1%) | ||
Smoking | 0.965 | 0.010 | |||||
Yes | 150 (31.9%) | 26 (31.7%) | 124 (32.0%) | 110 (35.9%) | 40 (24.4%) | ||
No | 320 (68.1%) | 56 (68.3%) | 264 (68.0%) | 196 (64.1%) | 124 (75.6%) | ||
Alcohol | 0.636 | 0.135 | |||||
Yes | 89 (18.9%) | 14 (17.1%) | 75 (19.3%) | 64 (20.9%) | 25 (15.2%) | ||
No | 381 (81.1%) | 68 (82.9%) | 313 (80.7%) | 242 (79.1%) | 139 (84.8%) | ||
Gross appearance | 0.549 | 0.044 | |||||
Bulge | 139 (29.6%) | 22 (26.8%) | 117 (30.2%) | 100 (32.7%) | 39 (23.8%) | ||
Infiltration or ulcer | 331 (70.4%) | 60 (73.2%) | 271 (69.8%) | 206 (67.3%) | 125 (76.2%) | ||
Histological type | 0.123 | 0.574 | |||||
Adenocarcinoma | 437 (93.0%) | 73 (89.0%) | 364 (93.8%) | 286 (93.5%) | 151(92.1%) | ||
Mucinous adenocarcinoma or signet ring cell cancer | 33 (7.0%) | 9 (11.0%) | 24 (6.2%) | 20 (6.5%) | 13 (7.9%) | ||
T stage | 0.001 | 0.008 | |||||
T1–T2 | 104 (22.1%) | 7 (8.5%) | 97 (25.0%) | 79 (25.8%) | 25 (15.2%) | ||
T3–T4 | 366 (77.9%) | 75 (91.5%) | 291 (75.0%) | 227 (74.2%) | 139(84.8%) | ||
N stage | 0.807 | 0.697 | |||||
N0–N1 | 394 (83.8%) | 68 (82.9%) | 326 (84.0%) | 258 (84.3%) | 136 (82.9%) | ||
N2–N3 | 76 (16.2%) | 14 (17.1%) | 62 (16.0%) | 48 (15.7%) | 28 (17.1%) | ||
TNM stage | 0.526 | 0.313 | |||||
I–II | 284 (60.4%) | 47 (57.3%) | 237 (61.1%) | 190 (62.1%) | 94 (57.3%) | ||
III | 186 (39.6%) | 35 (42.7%) | 151 (38.9%) | 116 (37.9%) | 70 (42.7%) | ||
Differentiated degree | 0.006 | 0.499 | |||||
Well/moderate | 73 (15.5%) | 61 (74.4%) | 336 (86.6%) | 261 (85.3%) | 136 (82.9%) | ||
Poor/undifferentiated | 397 (84.5%) | 21 (25.6%) | 52 (13.4%) | 45 (14.7%) | 28 (17.1%) | ||
Nerve invasion | 0.044 | 0.670 | |||||
Positive | 84 (17.9%) | 21 (25.6%) | 63 (16.2%) | 53 (17.3%) | 31 (18.9%) | ||
Negative | 386 (82.1%) | 61 (74.4%) | 325 (83.8%) | 253 (82.7%) | 133 (81.1%) | ||
Intravascular tumor emboli | 0.377 | 0.557 | |||||
Positive | 87 (18.5%) | 18 (22.0%) | 69 (17.8%) | 59 (19.3%) | 28 (17.1%) | ||
Negative | 383 (81.5%) | 64 (78.0%) | 319 (82.2%) | 247 (80.7%) | 136 (82.9%) | ||
CEA | 0.192 | 0.004 | |||||
High | 171 (36.4%) | 35 (42.7%) | 136 (35.1%) | 97 (31.7%) | 74 (45.1%) | ||
Normal | 299 (63.6%) | 47 (57.3%) | 252 (64.9%) | 209 (68.3%) | 90 (54.9%) | ||
ALB (g/L), median (IQR) | 40.6 (37.8, 43.2) | 40.0 (36.5, 42.5) | 40.8 (38.1, 43.5) | 0.008 | 41.6 (39.1, 44.4) | 38.4(36.2, 41.1) | < 0.001 |
PLT (109/L), median (IQR) | 240 (198, 290) | 317 (250, 375) | 232 (192, 268) | < 0.001 | 233 (193, 266) | 267 (214, 330) | < 0.001 |
NE (109/L), median (IQR) | 3.62 (2.92, 4.52) | 5.60 (4.65, 6.62) | 3.38 (2.84, 4.03) | < 0.001 | 3.54 (2.85, 4.30) | 3.83 (3.11, 4.88) | 0.002 |
MONO (109/L), median (IQR) | 0.45 (0.35, 0.56) | 0.42 (0.33, 0.51) | 0.64 (0.56, 0.78) | < 0.001 | 0.43 (0.35, 0.53) | 0.46 (0.38, 0.60) | 0.002 |
LY (109/L), median (IQR) | 1.79 (1.45, 2.19) | 1.56 (1.30, 2.10) | 1.84 (1.50, 2.20) | 0.003 | 1.77 (1.42, 2.15) | 1.88 (1.50, 2.28) | 0.042 |
